VANCOUVER, BC, Feb. 3, 2022 /CNW/ - NeutriSci International
Inc. ("NeutriSci" or the "Company") (TSXV: NU)
(OTC PINK: NRXCF) (FRANKFURT: 1N9), an innovative technology
company developing products, licencing, IP and technology for B2B
partnerships and the nutraceutical industry, is pleased to provide
the following update.
Tabletz: On January
17th, the Company shipped an order for 45,000
sticks to Tabletz for distribution in Japan. The product was received by Tabletzs'
distribution partner CFC Japan Co. for further distribution across
the country to a national grocery chain, some convenience stores
and to replenish product in the Biopole stores. While some
shipping challenges remain, for the most part, the Company has
overcome those challenges and is positioned nicely for future
shipments to Japan. The Company is
working on completing an additional order to replenish the existing
stores as well building product for new stores to come online.
Tabletz is implementing a comprehensive marketing campaign in
Japan that includes social media,
traditional media, in-store programs, and sampling programs where
Covid restrictions allow. The next order is expected to ship in Q2.
Further details on distribution partners, marketing initiatives and
stores will follow.
Cryopharm: Cryopharm's partner, Red Bud Roots, has completed manufacturing and
started the distribution and sale of a small introductory order of
products that initially includes gummies, to the market.
Red Bud has distribution in 275
locations. They own licences for infusion, grow, extraction, sales
and distribution. NeutriSci is expected to realize revenue from its
licencing arrangement with Cryopharm in Q2 of this year. Cryopharm
also continues to move forward with their partnership with an
Oklahoma group. They have been
working on supporting roll out needs and will continue to do so
well into Q3. Timing for start of production is still unknown at
this time.
Neuenergy: NeutriSci's latest production of tablets
for the neuenergy® line has made its way to its national
distribution partner, ANB. The initial 1,500 case order will be
placed into ANB's distribution channel in Canada. Retailers include Overwaitea,
Mckesson, Sobey's, Safeway, Pharmasave, and Guardian. The
previously announced partnership and order with the German
marketing and distribution group, THIC, is on track to commence
distribution of neuenergy® in the European market in
Q2. An initial order for 10,000 units of resealable bulk bags
with 36 tablets each has already been placed and a deposit has been
received. The Company and THIC plan to release packaging,
distribution and sales details in the coming weeks.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and
formulation of nutraceutical products. Established in 2009,
NeutriSci's is building sustainable sales models with Convenience,
Chain Drug, and Mass Market and Supermarket retailers for its
products offering co-branding as well as private label
opportunities and contract manufacturing services. For more
information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accept responsibility for the adequacy or accuracy of
this release.
This news release may include forward-looking statements that
are subject to risks and uncertainties. All statements within,
other than statements of historical fact, are to be considered
forward-looking. Although the Company believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results or developments may differ
materially from those in forward-looking statements. Factors
that could cause actual results to differ materially from those in
forward-looking statements include market prices, continued
availability of capital and financing, and general economic, market
or business conditions. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised
to rely on their own evaluation of such uncertainties. We do
not assume any obligation to update any forward-looking statements
except as required under the applicable laws.
Statements in this press release have not been evaluated by
the Food and Drug Administration. Products or ingredients are
not intended to diagnose, treat, cure, or prevent any
disease.
SOURCE NeutriSci International Inc.
